There’s more than one reason why experts are excited by the potential of CSL. The post Here's one reason why experts think ...
The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working ...
CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The expansion, a cornerstone of the ...
Are the biotech company's shares worth holding onto? The post $5,000 invested in CSL shares 12 months ago is now worth… ...
CSL's strong building products portfolio and efficient capital allocation support stable margins, but certain headwinds limit growth opportunities. Recurring re-roofing revenues and operational ...
Brokers see significantly more upside ahead for Pro Medicus. The post Forget CSL shares, this ASX healthcare stock could ...
Livewire Markets on MSN
Smashed, shunned… but this fundie is buying CSL and 2 more healthcare plays
After a brutal year for healthcare stocks, one portfolio manager says several areas now look surprisingly attractive.
Business remains robust and brokers see ASX stock soaring up to 100%. The post CSL shares look primed to take off — Here's ...
CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...
The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines "CSL's growing R&D presence in Waltham is the latest example of our ...
CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results